U.S. Pharmacist Weekly News Update
October 2, 2019

Use of ACE Inhibitors
Linked to 24% Drop
in Type 2 Diabetes Risk

While medications to lower blood pressure might all meet their primary purpose, other factors should come into play, according to a new study. Find out how much taking ACE inhibitors lowers the risk of developing type 2 diabetes compared with placebo in patients taking them.


FDA Approves First Oral
GLP-1 Treatment for Use
in Type 2 Diabetes

Pharmacists who deal with needle-phobic patients with type 2 diabetes should applaud the FDA’s approval of the first oral glucagon-like peptide receptor protein treatment. Like the injected versions, however, the new drug still has prescribing information that limits usage in some type 2 diabetes patients. Here is more information.

Sertraline Reduces Anxiety, Not Depression, in First 6 Weeks
Pharmacists might be surprised by new information on what happens when patients take sertraline, marketed as Zoloft. Researchers found strong evidence it reduces anxiety in the first 6 weeks, but weaker evidence that it resolves depressive symptoms over 12 weeks. Here are more details.

More Evidence of Link
Between Antibiotic Use,
C Difficile in Hospitals

Which antibiotics are most likely to increase the risk of Clostridioides difficile  in hospitals and how does their use affect prevalence of the sometimes fatal gastrointestinal illness? A new study looked at the issue, and here is what CDC researchers and colleagues found.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App